Inclisiran (Leqvio) — Global Competitive Landscape Report 2026

Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.

Executive Summary

Moreover, inclisiran (Inclisiran sodium / Leqvio) — Novartis’s first-in-class PCSK9-targeting small interfering RNA (siRNA) therapeutic with twice-yearly subcutaneous dosing — has emerged as the most clinically and commercially important RNA therapeutic in cardiovascular medicine since FDA approval in December 2020 (EMA approval December 2020 first). Notably, Inclisiran remains active in 68 ongoing clinical trials including 17 Phase 3, 15 Phase 4, 16 Not Applicable, 1 Phase 2, and 1 Phase 1 trials, with 9 patent filings since January 2023 covering manufacturing, lifecycle, and combination protections plus 7 disclosed business development deals.

Specifically, Inclisiran’s commercial trajectory has been transformed by sequential FDA approvals across heterozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) on December 2021, plus EMA approval in December 2020. Moreover, ongoing Phase 4 V-INVINCIBLE Chinese pragmatic trial, ORION-4 cardiovascular outcomes trial, VICTORION-2P, VICTORION-INITIATE, and emerging dual PCSK9 + alirocumab combination Phase 4 trials extend the franchise across heterozygous FH adolescents, post-MI early intensive lipid lowering, and atherosclerotic disease prevention. Furthermore, Inclisiran represents the foundation of Novartis’s broader cardiovascular RNA therapeutic franchise.

However, the strategic outlook is increasingly defined by competing PCSK9 modalities and the broader Novartis-NHS partnership model rather than incremental siRNA chemistry. As a result, Inclisiran’s commercial trajectory depends on positioning relative to Amgen Repatha (Evolocumab PCSK9 mAb) and Sanofi/Regeneron Praluent (Alirocumab PCSK9 mAb), emerging Verve Therapeutics VERVE-102 (PCSK9 base-editing one-time treatment), Merck Enlicitide (oral PCSK9 macrocyclic peptide), Lerodalcibep (LIB Therapeutics PCSK9 mAb FDA approval December 2025), and Junshi Biosciences Ongericimab (China-developed PCSK9 mAb). Furthermore, ORION-4 cardiovascular outcomes Phase 3 readouts will determine whether Inclisiran captures CV outcome label expansion comparable to Repatha’s FOURIER and Praluent’s ODYSSEY OUTCOMES.

---

Traditionally, compiling this level of single-drug analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.

Drug Profile Overview

Mechanism & Approved Indications

However, inclisiran is a chemically modified, double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc) for selective hepatocyte uptake via the asialoglycoprotein receptor. Specifically, the molecule directs intracellular degradation of PCSK9 mRNA via the RNAi pathway, thereby reducing circulating PCSK9 protein and increasing hepatic LDL receptor recycling. Moreover, Inclisiran was originally developed by The Medicines Company through licensing from Alnylam Pharmaceuticals; Novartis acquired global rights through The Medicines Company acquisition in 2020 ($9.7B). Furthermore, Inclisiran’s twice-yearly subcutaneous dosing (after initial month-2 booster) provides differentiated patient adherence versus monthly/bi-weekly PCSK9 mAbs.

Trial Activity

In addition, the active clinical-stage program around Inclisiran totals 68 trials, with 17 in Phase 3, 15 in Phase 4 post-marketing, 16 not applicable studies, 1 Phase 2, and 1 Phase 1. Notably, key Phase 3/4 trials include ORION-4 (cardiovascular outcomes in established ASCVD), VICTORION-2P (secondary prevention), VICTORION-INITIATE (statin-naive primary prevention), V-INVINCIBLE (Chinese pragmatic randomized trial, Phase 4), PCSK9-DUO (dual PCSK9 inhibition with Alirocumab in secondary prevention), and Inclisiran in HoFH adolescents Phase 3 (completed). Furthermore, real-world effectiveness studies plus early in-hospital initiation post-MI trials extend the evidence base into chronic disease management settings.

Clinical Evidence Snapshot

Indication	Trial	Stage	Strategic Positioning
HeFH + ASCVD (LDL-C reduction)	ORION-9, ORION-10, ORION-11	Approved 2020-2021	FDA + EMA approvals; foundation
HeFH adolescents	Phase 3	Completed	Adolescent label expansion
Cardiovascular outcomes (ASCVD)	ORION-4	Phase 3 (active)	CV outcomes pivotal — competes with FOURIER + ODYSSEY OUTCOMES
Secondary prevention	VICTORION-2P	Phase 3 (active)	Earlier-line CVD prevention
Statin-naive primary prevention	VICTORION-INITIATE	Phase 3	1L lipid lowering positioning
Chinese pragmatic effectiveness	V-INVINCIBLE	Phase 4 (active not recruiting)	Real-world Chinese commercial validation
Dual PCSK9 inhibition (Inclisiran + Alirocumab)	PCSK9-DUO	Phase 4 (not yet recruiting)	Combination strategy in secondary prevention
Post-MI early in-hospital initiation	Phase 3	Recruiting	Acute coronary syndrome positioning

---

Competitive Positioning

PCSK9 Modality Comparator Matrix

Molecule	Sponsor	Format	Dosing	Strategic Position
Inclisiran (Leqvio)	Novartis	siRNA conjugated to GalNAc	Twice-yearly SC	Tier 1 — Convenience leader
Evolocumab (Repatha)	Amgen	Anti-PCSK9 mAb	Monthly or bi-weekly SC	Tier 1 — CV outcomes incumbent
Alirocumab (Praluent)	Sanofi / Regeneron	Anti-PCSK9 mAb	Bi-weekly or monthly SC	Tier 1 — ODYSSEY OUTCOMES
Lerodalcibep	LIB Therapeutics	Anti-PCSK9 mAb	Monthly SC	Tier 2 — FDA approval Dec 2025
Ongericimab	Junshi Biosciences	Anti-PCSK9 mAb	SC	Tier 2 — China NMPA
Tafolecimab	Innovent Biologics	Anti-PCSK9 mAb	SC	Tier 2 — China NMPA
Enlicitide (MK-0616)	Merck & Co.	Oral macrocyclic peptide	Daily oral	Tier 1 emerging — first oral PCSK9
VERVE-102	Verve Therapeutics	PCSK9 base-editing	One-time IV infusion	Tier 1 emerging — curative-intent
Olpasiran	Amgen	Lp(a) siRNA	Quarterly SC	Tier 2 — adjacent Lp(a) target
Pelacarsen	Novartis / Ionis	Lp(a) ASO	Monthly SC	Tier 2 — adjacent Lp(a) target

Strategic Comparison vs. PCSK9 mAbs

Notably, Inclisiran’s twice-yearly subcutaneous dosing provides the most differentiated patient adherence proposition in the PCSK9 class versus monthly/bi-weekly Repatha and Praluent. Specifically, the two-injection-per-year regimen supports primary care prescribing infrastructure where chronic injection adherence has historically limited PCSK9 mAb commercial scaling. Furthermore, the Novartis-NHS partnership model (January 2020) established a precedent for population-level access pricing that PCSK9 mAbs cannot easily replicate. However, Inclisiran does not yet have CV outcomes label data — ORION-4 readouts (anticipated 2027-2028) will determine whether Inclisiran can match Repatha’s FOURIER and Praluent’s ODYSSEY OUTCOMES CV outcomes positioning.

Strategic Comparison vs. Oral PCSK9 + Gene Editing

Furthermore, the long-term competitive threats to Inclisiran come from Merck’s Enlicitide (oral macrocyclic peptide PCSK9, Phase 3) and Verve Therapeutics’s VERVE-102 (PCSK9 base-editing one-time treatment). Specifically, Enlicitide’s daily oral format competes with Inclisiran’s twice-yearly injection on the convenience axis differently — daily oral may be preferred by some patients while twice-yearly injection captures non-adherent populations. Moreover, VERVE-102’s potential one-time PCSK9 base-editing could fundamentally transform cardiometabolic management by eliminating chronic dosing entirely. As a result, Inclisiran’s commercial trajectory in 2030 depends on whether Novartis can establish sufficient CV outcomes evidence and earlier-line positioning before Enlicitide and VERVE-102 establish alternative formats.

Combination Strategy

In addition, Inclisiran’s PCSK9-DUO Phase 4 trial (dual PCSK9 inhibition with Alirocumab in secondary prevention) represents a novel combination strategy that addresses patients with persistent LDL-C elevation despite single-mechanism PCSK9 blockade. Specifically, dual PCSK9 inhibition combining Inclisiran (intracellular PCSK9 mRNA suppression) with Alirocumab (extracellular PCSK9 protein neutralization) may produce additive LDL-C reduction. Furthermore, emerging Lp(a)-targeted siRNA (Olpasiran) and ASO (Pelacarsen) plus Inclisiran combinations represent the next-generation cardiometabolic combination strategy.

---

Patent & Lifecycle Strategy

Patent Filing Activity

As a result, patent activity since 2023 totals 9 filings around Inclisiran covering manufacturing process improvements (siRNA synthesis, GalNAc conjugation), formulation refinements, companion biomarker diagnostics, and combination protections. Notably, the relatively limited filing volume reflects Inclisiran’s status as a single-molecule franchise with established composition-of-matter and method-of-use patents from the original Alnylam-Medicines Company licensing era; Novartis’s lifecycle defense focuses on combination strategies and manufacturing process improvements rather than novel chemistry.

BD Deal Timeline

Date	Deal	Counterparty	Type	Significance
2025-08	Bluemtec / Novartis Korea Leqvio distribution	Bluemtec (Korea)	Distribution	Korean neighborhood clinics expansion
2021-09	Novartis-NHS England Leqvio access agreement	NHS England + Novartis	Population health	World-first national PCSK9 siRNA access
2020-04	Blackstone-Alnylam strategic financing	Blackstone + Alnylam	Financing	$2B for siRNA platform development
2020-04	Novartis / The Medicines Company acquisition	Novartis ← The Medicines Company	M&A	$9.7B for global Inclisiran rights
2020-01	NHS-Novartis collaboration agreement	NHS England + Novartis	Strategic partnership	Foundation for population access pricing
2024-2025	Multiple regional distribution agreements	Multiple regional partners	Distribution	Global commercial expansion

Strategic Pattern

Notably, the BD landscape has been dominated by Novartis’s $9.7B The Medicines Company acquisition (2020) integrating global Inclisiran rights, plus the world-first NHS England population-level access agreement that established the “value-based access” pricing model. Furthermore, the Blackstone-Alnylam $2B strategic financing (2020) supported Inclisiran’s broader siRNA platform development. However, no major outbound Inclisiran BD has occurred recently — Novartis retains internal franchise control with regional distribution arrangements (e.g., Bluemtec Korea 2025-08).

---

Unmet Needs & Strategic White Spaces

Opportunity Matrix

Strategic Gap	Current Status	Competitive Pressure	White Space
Cardiovascular outcomes data	ORION-4 + VICTORION-2P Phase 3	Repatha FOURIER, Praluent ODYSSEY OUTCOMES	CV outcomes label expansion
Pediatric / adolescent HoFH + HeFH	HeFH adolescents Phase 3 complete	Limited approved options	Pediatric label + adolescent expansion
Statin-intolerant + statin-naive primary prevention	VICTORION-INITIATE Phase 3	Bempedoic acid + ezetimibe	1L cardiovascular prevention positioning
Chinese commercial scaling	V-INVINCIBLE Phase 4 active	Multiple Chinese PCSK9 mAbs (Tafolecimab, Ongericimab)	Pragmatic real-world data
Dual PCSK9 mechanism combination	PCSK9-DUO Phase 4 (not yet recruiting)	Limited approved combinations	siRNA + mAb combination strategy

---

Risks and Strategic Outlook for 2026 and Beyond

Key Risks

1. Notably, ORION-4 cardiovascular outcomes Phase 3 readouts carry significant binary risk; failure to demonstrate clear CV outcomes would constrain Inclisiran’s broader prescribing and reimbursement.
2. Moreover, emerging Verve VERVE-102 PCSK9 base-editing one-time treatment represents the most strategically significant long-term threat by potentially eliminating chronic dosing entirely.
3. However, Merck Enlicitide oral macrocyclic peptide PCSK9 launch in 2026-2027 may capture the convenience-driven primary care segment that Inclisiran has been positioning for.
4. In addition, Chinese-developed PCSK9 mAbs (Tafolecimab, Ongericimab, Lerodalcibep) compress emerging-market commercial pricing; Inclisiran’s premium price point requires sustained value differentiation.

Strategic Outlook

Overall, Inclisiran has consolidated as the most clinically and commercially important PCSK9-targeting RNA therapeutic globally, with leadership across PCSK9 siRNA mechanism, twice-yearly dosing convenience, and population-level access partnership models. Furthermore, the next 24 to 36 months will be defined by ORION-4 cardiovascular outcomes Phase 3 readouts, V-INVINCIBLE Chinese pragmatic effectiveness data, VICTORION program 1L positioning, PCSK9-DUO dual mechanism combination data, and the maturation of Verve VERVE-102 + Merck Enlicitide competitive dynamics. Meanwhile, dual PCSK9 + Lp(a) siRNA combinations and emerging cardiovascular RNA therapeutic platform extension represent the longer-term differentiation that could reshape cardiometabolic management by 2030.

If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.